Related Experiment Videos
Oral anticoagulants are effective long-term after acute myocardial infarction
1Department of Medicine, Baerum Hospital, Norway. pasm@online.no
Insights
Oral anticoagulation significantly reduces recurrent heart attacks and stroke risk after myocardial infarction. The WARIS study also showed a significant decrease in all-cause mortality, offering substantial patient benefits with careful management.
Area of Science:
- Cardiovascular Medicine
- Clinical Trials
- Pharmacology
Background:
- Oral anticoagulation is a critical treatment strategy following myocardial infarction (MI).
- Evaluating the long-term efficacy and safety of anticoagulation requires rigorous clinical trial methodologies.
- Previous studies have indicated benefits, but comprehensive analysis of mortality reduction is essential.
Purpose of the Study:
- To assess the efficacy of oral anticoagulation in reducing adverse events post-myocardial infarction.
- To determine the impact of oral anticoagulation on all-cause mortality.
- To evaluate the overall benefit-risk profile, including bleeding incidence, of long-term anticoagulation therapy.
Main Methods:
- Analysis of three large-scale, long-term clinical trials: Sixty Plus, WARIS, and ASPECT.
- Inclusion criteria focused on trials with modern methodological standards: large patient numbers, double-blinded, placebo-controlled design, and intention-to-treat analysis.
- Meta-analysis to confirm findings and consolidate evidence on anticoagulation efficacy.
Main Results:
- All three trials demonstrated a significant reduction in recurrent myocardial infarction.
- All studies showed a reduction in the risk of total stroke.
- The WARIS study uniquely reported a statistically significant reduction in all-cause mortality, a finding supported by meta-analysis.
Conclusions:
- Oral anticoagulation provides significant benefits in preventing recurrent MI and stroke after MI.
- The WARIS study highlights the potential of anticoagulation to reduce all-cause mortality.
- With appropriate management and control methods, the benefits of oral anticoagulation outweigh the risks of bleeding.
Abstract:
Three long-term studies on oral anticoagulation, the Sixty Plus trial, the WARIS study, and the ASPECT trial all meet the methodological requirements for modern stand alone clinical trials: large number of patients, double-blinded, placebo-controlled design, and intention to treat analysis. All demonstrate significant reduction in recurrent myocardial infarction, and all show reduction in the risk of total stroke. The WARIS study, however, is the only study demonstrating efficacy in terms of statistically significant reduction of all-cause mortality. These findings are confirmed by a recent meta-analysis. The overall benefit of oral anticoagulation after myocardial infarction suggests avoidance of 4-26 events per 100 patients treated for 2-3 years. Given the results from the trials applying the most adequate control of anticoagulation, avoidance of 10-14 events per 100 patients treated seems to be a realistic benefit. Provided there is sound management of the anticoagulant therapy, especially employment of suitable control methods, the incidence of bleeding may be kept at a low level.